Compare Firy Inc. (FIRY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Incyte Corporation — how do they compare? Firy Inc. trades at $12.07 (market cap $199.80M), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 114.4× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Incyte Corporation for 33 Days on average.
| FIRY | INCY | |
|---|---|---|
Market Cap | $199.80M | $22.85B |
Volume | 92,993 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $13.10 | $129.93 |
52-Week Low | $2.28 | $83.80 |
Typical Hold Time | 13 Days | 33 Days |
Enterprise Value | $168.40M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.02, up 1.43% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but missed EPS expectations with a net loss. Recent developments include a $719M legal victory and board appointment of Marc Lasry, though cash flow remains negative with -$86.41M in 2025.
Outlook is mixed: the legal win and restructuring offer potential upside, but persistent losses and cash burn pose significant risks. Analyst consensus is cautious with 60% hold ratings. The stock's valuation at P/S 1.6x appears reasonable, but profitability challenges and negative margins require careful monitoring.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
